Article Text

Download PDFPDF
Rapid resolution of choroidal metastatic tumour secondary to lung cancer following treatment with alectinib
  1. Ahmed AL-Janabi1,
  2. May Thu Han2,
  3. Deborah Busby1 and
  4. Benjamin J L Burton1
  1. 1Ophthalmology Department, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK
  2. 2James Paget University Hospital NHS Foundation Trust, Great Yarmouth, UK
  1. Correspondence to Dr Ahmed AL-Janabi; a.kasb{at}ucl.ac.uk

Abstract

A 64-year-old man presented with reduced vision in the right eye (visual acuity of 6/24 Snellen). The patient reported having a chronic cough and recent weight loss with difficulty in swallowing and abnormal liver function test 8 months prior to his presentation. He was a chronic smoker for 45 years, having quit a year earlier. Fundus examination showed a unifocal large yellow–brown subretinal mass involving the posterior segment of the eye and associated with subretinal fluid. The patient was diagnosed with a choroidal metastasis and was referred urgently to the oncology team who confirmed the presence of non-small cell lung cancer with distant metastases. He started treatment with alectinib (second-generation tyrosine kinase inhibitor). A few weeks later, his vision improved and, on examination, there was complete resolution of the choroidal mass and the associated subretinal fluid. Alectinib led to rapid resolution of his choroidal secondary and has excellent ocular safety profile.

  • medical management
  • cancer - see oncology
  • eye
  • lung cancer (oncology)
  • retina

Statistics from Altmetric.com

Footnotes

  • Contributors This work was written by AA-J and edited by MTH. Images were provided by DB. The final version was approved by BJLB.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer-reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.